Results 121 to 130 of about 1,098,931 (194)

Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS). [PDF]

Am J Hematol
Man L, Kanack AJ, Mauch EE, Splinter NP, Padmanabhan A.   +4 more
europepmc   +1 more source

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]

Am J Cardiovasc Drugs
Spadafora L, Russo F, Bukowska-Olech E, Panichella G, Garofalo M, Cacciatore S, Sabouret P, Sarto G, Simeone B, Rocco E, Lauretti A, Versaci F, Zoccai GB, Colaiori I, Valenti V, Sciarretta S, Bernardi M.   +16 more
europepmc   +1 more source

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

Open Forum Infect Dis
Aparicio-Minguijón E, López-Muñoz N, Boán J, Pérez-Jacoiste Asín MA, de la Serna J, Pérez-Ayala A, Enguita AB, Rodríguez-Goncer I, Fernández-Ruiz M.   +8 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study. [PDF]

ASM Case Rep
Bhaimia E, Russell D, Santos CAQ.
europepmc   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

Blood Res
Hur JY, Lee JH, Lee JH, Park HS, Park H, Choi Y, Choi JH, Won YW, Yoon SE, Kim WS, Kim SJ.   +10 more
europepmc   +1 more source

<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]

EJHaem
Haméon C, Houot R, Gyan E, Vallet N, Lachot S, Ganard M, Herault O, De Guibert S, Pastoret C, Dartigeas C.   +9 more
europepmc   +1 more source

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review. [PDF]

Curr Ther Res Clin Exp, 2022
Rezaei M, Barati S, Babamahmoodi A, Dastan F, Marjani M.   +4 more
europepmc   +1 more source

Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. [PDF]

Cardiooncology
Aurer I, Bulj N, Demirevska L, Dragnić S, Dreisinger M, Goranova-Marinova V, Jakšić O, Lipar L, Rener K, Spassov B, Urošević I, Vukovic V, Žarić E, Zdravković M.   +13 more
europepmc   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. [PDF]

Blood Adv, 2022
Di M, Cui C, Kothari SK, Zeidan AM, Podoltsev NA, Neparidze N, Shallis RM, Wang R, Ma X, Huntington SF.   +9 more
europepmc   +1 more source